CHICAGO — Emalex Biosciences announced the closing of an upsized and oversubscribed $250 million Series D funding round that will fund a Phase 3 clinical trial and potential commercialization of a new class of drug for patients with Tourette Syndrome. ‘
Bain Capital Life Sciences led the funding round with participation from Paragon Biosciences, Valor Equity Partners, Fidelity Management & Research Compnay and several family offices.
Emalex’s Phase 3 clinical trial for its investigational first-in-class new drug ecopipam, a novel dopamine-1 receptor antagonist, is expected to enroll more than 220 patients across approximately 90 sites, making it the largest trial ever conducted in North America for this serious central nervous system disorder.
Emalex Biosciences was created by Paragon Biosciences in 2018 to develop novel treatments for central nervous system (CNS) disorders.
“Emalex was founded specifically to tackle serious neurological conditions like Tourette Syndrome, recognizing that drug development for neurologic conditions is exceptionally difficult and few companies are willing to invest in bringing new options to these patients,” said Jeff Aronin, Emalex founder and Paragon Biosciences CEO. “Our team has a strong track record of success developing neurology drugs and we are pleased to partner with our investors to advance ecopipam for patients.”
The funding comes following positive Phase 2b clinical trial results (D1AMOND Study) that showed the investigational new drug ecopipam reduced motor and phonic tics as compared to placebo. The most frequent adverse events related to ecopipam in the study were headache, fatigue, somnolence, insomnia and restlessness. Patients in the trial did not have observable evidence of adverse movement or metabolic side effects commonly reported with antipsychotic agents.
Tourette Syndrome is associated with both increased mortality and significant morbidity. In the majority of individuals, Tourette substantially impacts day-to-day physical and social function.
“Tic disorders can have severe social and psychological consequences for patients, and there currently aren’t many medications that effectively reduce tics without causing unhealthy side effects. Ecopipam has a novel mechanism that targets the D1 receptor, which is a new class of neurology drug,” said Donald Gilbert, MD, a movement disorders specialist at the Cincinnati Children’s Hospital. “It’s important to note that a large number of patients with Tourette Syndrome have co-morbidities like ADHD or OCD. During the Phase 2b study they were allowed to continue their medications for those conditions, and their Tourette symptoms measurably improved with ecopipam.”
